Organon, Shanghai Henlius: EC approves marketing for Bildyos, Bilprevda

Shanghai Henlius Biotech and Organon (OGN) announced the European Commission has granted marketing authorization for BILDYOS injection 60 mg/mL and BILPREVDA injection 120 mg/1.7 mL, biosimilars to PROLIA and XGEVA, respectively, for all indications of the reference products. In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to several biosimilars, including BILDYOS and BILPREVDA. The agreement covers exclusive global commercialization rights except for China